Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project
Overview
Authors
Affiliations
Background And Purpose: Standard assessment criteria for brain tumors that only include anatomic imaging continue to be insufficient. While numerous studies have demonstrated the value of DSC-MR imaging perfusion metrics for this purpose, they have not been incorporated due to a lack of confidence in the consistency of DSC-MR imaging metrics across sites and platforms. This study addresses this limitation with a comparison of multisite/multiplatform analyses of shared DSC-MR imaging datasets of patients with brain tumors.
Materials And Methods: DSC-MR imaging data were collected after a preload and during a bolus injection of gadolinium contrast agent using a gradient recalled-echo-EPI sequence (TE/TR = 30/1200 ms; flip angle = 72°). Forty-nine low-grade ( = 13) and high-grade ( = 36) glioma datasets were uploaded to The Cancer Imaging Archive. Datasets included a predetermined arterial input function, enhancing tumor ROIs, and ROIs necessary to create normalized relative CBV and CBF maps. Seven sites computed 20 different perfusion metrics. Pair-wise agreement among sites was assessed with the Lin concordance correlation coefficient. Distinction of low- from high-grade tumors was evaluated with the Wilcoxon rank sum test followed by receiver operating characteristic analysis to identify the optimal thresholds based on sensitivity and specificity.
Results: For normalized relative CBV and normalized CBF, 93% and 94% of entries showed good or excellent cross-site agreement (0.8 ≤ Lin concordance correlation coefficient ≤ 1.0). All metrics could distinguish low- from high-grade tumors. Optimum thresholds were determined for pooled data (normalized relative CBV = 1.4, sensitivity/specificity = 90%:77%; normalized CBF = 1.58, sensitivity/specificity = 86%:77%).
Conclusions: By means of DSC-MR imaging data obtained after a preload of contrast agent, substantial consistency resulted across sites for brain tumor perfusion metrics with a common threshold discoverable for distinguishing low- from high-grade tumors.
Abbad Andaloussi M, Maser R, Hertel F, Lamoline F, Husch A Neurooncol Adv. 2025; 7(1):vdae197.
PMID: 39877749 PMC: 11773385. DOI: 10.1093/noajnl/vdae197.
Mask region-based convolutional neural network and VGG-16 inspired brain tumor segmentation.
Basha N, Ananth C, Muthukumaran K, Sudhamsu G, Mittal V, Gared F Sci Rep. 2024; 14(1):17615.
PMID: 39080324 PMC: 11289405. DOI: 10.1038/s41598-024-66554-4.
Anil A, Stokes A, Karis J, Bell L, Eschbacher J, Jennings K AJNR Am J Neuroradiol. 2024; 45(10):1545-1551.
PMID: 38782593 PMC: 11448978. DOI: 10.3174/ajnr.A8357.
Tang L, Wu T, Hu R, Gu Q, Yang X, Mao H Quant Imaging Med Surg. 2024; 14(4):2774-2787.
PMID: 38617153 PMC: 11007532. DOI: 10.21037/qims-23-1471.
Zedde M, Napoli M, Moratti C, Pavone C, Bonacini L, Cecco G Diagnostics (Basel). 2024; 14(6).
PMID: 38535038 PMC: 10969781. DOI: 10.3390/diagnostics14060618.